Experience with hemoadsorption (CytoSorb<sup>®</sup>) in the management of septic shock patients
Yatin Mehta, Chitra Mehta, Ashish Kumar, Joby V. George, Aditi Gupta, Saurabh Nanda, Gourav Kochhar, Arun Raizada
Abstract
BACKGROUND: Cytokines and inflammatory mediators are the hallmarks of sepsis. Extracorporeal cytokine hemoadsorption devices are the newer clinical support system to overcome the cytokine storm during sepsis. AIM: To retrospectively evaluate the clinical outcomes of patients admitted in intensive care unit with septic shock with different etiologies. METHODS: The laboratory parameters including biomarkers such as procalcitonin, serum lactate and C-reactive protein; and the hemodynamic parameters; mean arterial pressure, vasopressor doses, sepsis scores, cytokine levels and other vital parameters were evaluated. We evaluated these outcomes among survivors and non-survivors. RESULTS: therapy less than 48 h after onset of septic shock survived and the maximum duration of stay for 70% of these patients in intensive care unit was less than 15 d. CONCLUSION: is a safe and well tolerated rescue therapy option in patients with septic shock. However, early (preferably within < 48 h after onset of septic shock) initiation could result in better clinical outcomes. Further randomized trials are needed to define the potential benefits of this new treatment modality.